Aluminium:Alzheimer's Disease Time to test the link By Professor Christopher Exley

6.9% funded

£500,000.00 the goal


£34,559.39 pledged so far from 124 backers
View this project's backers >

Latest Backers

  • Ketan Sheth : £129.36
  • Anonymous : £5.00
  • Joel Valento : £100.00
  • Angelika Stalman : £50.00
  • Anonymous : £10,000.00
  • John Eaton : £50.00
  • Anonymous : £72.96
  • Anonymous : £15,880.00
  • Anonymous : £317.75
  • Fuyu Wang : £318.35
  • MARIAM Umar : £7.80
  • Anonymous : £5.00
  • Duncan Best : £94.60
  • Ruben Mieling : £10.72
  • Anonymous : £7.85
  • Willow Fiduciaries : £1,000.00
  • Christine Parseghian : £32.07
  • Kerry Shardlow : £10.00
  • Anonymous : £7.09
  • Anonymous : £20.00
  • Candace Hart : £322.70
  • Anonymous : £100.00
  • Anonymous : £10.00
  • Doug Cross : £500.00
  • Liz Vaughan : £500.00
  • Ann Wills : £25.00
  • Zach Jones : £10.00
  • Mindy Gould : £6.40
  • Vern Saboe : £96.02
  • Sandra Gass : £50.00
  • Julie Jones : £50.00
  • Jennifer Dean : £75.00
  • Don Newton : £100.00
  • Anonymous : £20.00
  • Teresa Wright : £10.00
  • Anonymous : £5.00
  • Chris Cooke : £100.00
  • Joy Warren : £200.00
  • Jeannette Bishop : £16.04
  • Johan Bobacka : £10.00
  • Morag Lear : £20.00
  • Morag Lear : £25.00
  • Anonymous : £322.40
  • Susan Vitka : £500.00
  • Anonymous : £64.47
  • Peter C K Smith : £10.00
  • Ralph Nurnberger : £161.22
  • Anonymous : £100.00
  • Aleksandar Radu : £20.00
  • Toni Ehrlich-Feldman : £16.01
  • J'Nelle Hamilton : £64.06
  • Chrystelle Egger : £10.00
  • Linda Englander : £32.06
  • Leslie Manookian : £80.00
  • Laura Hayes : £160.20
  • Victor Cerullo : £20.00
  • Michael Eiden : £50.00
  • ray griffiths : £50.00
  • Patricia Cowan : £64.23
  • Randy Powers : £40.00
  • Eik Haraldsdottir : £10.00
  • Anonymous : £17.40
  • Erica Siegel : £192.42
  • Sue Andrews : £5.00
  • Steven Thompson : £100.00
  • Siobhan Justin : £32.13
  • Rosalie Reid : £20.00
  • Matteo Dall'Osso : £6.96
  • Tâmie Duarte : £5.03
  • Rosanne Lindsay : £64.09
  • Anonymous : £64.09
  • Ruben Mieling : £10.41
  • Bert Ehgartner : £34.70
  • Jose Dorea : £65.00
  • Anonymous : £8.36
  • Rosemary Mackay : £10.00
  • Sylvia Fogel M.D. : £320.30
  • Anonymous : £10.00
  • Michael Evans : £10.00
  • Joanna Read : £35.00
  • Lisa Rump : £10.00
  • Yasmine Lavizzari : £150.00
  • Arlene Preston : £20.00
  • Lisa Bloomquist : £15.00
  • Anonymous : £6.39
  • Zoey O'Toole : £12.79
  • Teresa Powell : £12.79
  • Interior Concepts : £63.96
  • Esko Meloni : £70.07
  • Amanda Dew : £100.00
  • Caroline Linhart : £14.10
  • Anonymous : £35.27
  • Julia Glendinning : £15.00
  • Anonymous : £20.00
  • Anonymous : £25.00
  • Anonymous : £6.39
  • Lukasz Mendecki : £1.00
  • Regitnig-Tillian Christa : £10.00
  • Victor Nuno : £31.98
  • Stephanie Seneff : £100.00
  • Alexandra Lütke Wissing : £7.04
  • Barton Rubenstein : £128.18
  • Anonymous : £64.15
  • Julia Cohen : £64.15
  • Anonymous : £1.00
  • Robert Krakow : £50.00
  • Anonymous : £1.00
  • Pip Brightmore : £1.00
  • Charlotte Nielsen : £10.00
  • Alexandria Brightmore : £20.00
  • Joakim Bang Larsen : £23.73
  • Anonymous : £5.00
  • Anonymous : £14.16
  • Sandy Lunoe : £50.00
  • Trudie Robinson : £20.00
  • Linda Flynn : £5.00
  • Deborah Goodall : £5.00
  • Anonymous : £5.00
  • Anonymous : £20.00
  • Anonymous : £5.00
  • Anonymous : £100.00
  • Anonymous : £10.00
  • Anonymous : £10.00

The first clinical trial testing the link between Alzheimer’s disease and Aluminium.

Opens 14 July 2015


What if a glass of water could prevent Alzheimer's?

Professor Chris Exley has been researching aluminium for over 30 years

Hello, my name is Chris Exley and sometimes known as Mr Aluminium. I consider the latter as a mark of respect. I have been researching and thinking about aluminium for over thirty years and I have published in excess of 150 scientific papers on this subject. 

For the specific purpose of raising funds for this important and historical clinical trial I am collaborating with the Children’s Medical Safety Research Institute (CMSRI) which is a registered 501(C)(3) non-profit organisation where I am a member of the Scientific Advisory Board. The CMSRI guarantees that 100% of net proceeds raised through this appeal will be made available for this clinical trial.

Testimonials in Support of this Project

"Fully Supportive"

George Perry, Ph.D.

Editor-in-Chief, Journal of Alzheimer's Disease

Dean and Professor,

Semmes Foundation Distinguished Chair in Neurobiology,

College of Sciences,

The University of Texas at San Antonio


High levels of aluminium MAY contribute towards Alzheimer’s disease

During the last ten years my group has investigated the link between aluminium and Alzheimer’s disease in more than 100 human brains and our findings have led us to one very simple conclusion2.

We must now accept that where the aluminium content of an individual’s brain tissue exceeds a certain level that this aluminium will contribute towards any ongoing Alzheimer’s disease in that individual 3, 4.

Recent research suggests that we can protect ourselves against the ravages of Alzheimer’s disease by taking measures to reduce our everyday exposure to aluminium5.  

We live in the ‘Age of Aluminium’

We live in the aluminium age and we have all benefitted enormously from technology which approximately 120 years ago allowed us to make aluminium metal and aluminium salts from inert stores of aluminium within the Earth’s crust.

Aluminium is now the most commonly and widely used metal on Earth and there are myriad ways in which we are exposed to it in our everyday lives including; our diet (particularly processed drinks and food); medicine (notably antacids, buffered aspirin, vaccinations); cosmetics (examples including antiperspirants and sun blocks); aerosols ( the air that we breathe can be full of particulate materials composed of aluminium).

Human exposure to aluminium is burgeoning and, assuming current projections of its extraction and use will have increased 100 fold between 1950 and 20506. Aluminium has no known benefit in any living organism, from virus to human beings, it is only toxic and it is only the activities of Man which have resulted in our increased exposure over the last 100 years or so.

Aluminium is the most ubiquitous ecological toxicant on Earth being responsible for the death of fish in acid lakes, the decline of forests in areas impacted by acid rain and the decline of food crops on acid sulphate soils. All effects which are attributable to the activities of Man7.

Helping the human body to deal with the burden of aluminium

While we cannot put the aluminium genie back in the bottle it would be complacent of us not to endeavour to use aluminium as safely and effectively as possible. Before we are able to understand the full extent of aluminium’s role in human disease it would be sensible to adopt a precautionary approach and specifically to take steps to help the human body deal with its burden of aluminium and more directly to help the body to excrete aluminium and so prevent its accumulation in potentially vulnerable areas such as the brain. We all excrete aluminium from our body in our urine. However, this does not prevent aluminium accumulating in the body with age. We have found that through regular drinking of mineral waters which are rich in silicon (more than 30 ppm silica) the excretion of aluminium in urine is facilitated in such a way that over extended periods of time aluminium is removed from the body. The body burden of aluminium can be significantly reduced.

This trial will tell us if aluminium is contributing to Alzheimer’s disease

The proposed clinical trial will not tell us if aluminium is a cause of Alzheimer’s disease. It will tell us if aluminium in our body is contributing to Alzheimer’s disease. This is powerful information and if we then choose to act upon it by reducing our everyday exposure to aluminium and helping the removal of aluminium from our body by making silicon-rich mineral waters a natural part of our everyday diet then for the very first time we will have the tools to fight back against such a devastating condition as Alzheimer’s disease.

Our major costs in planning and running this clinical trial will be the recruitment of participants and the following and monitoring of participants over time. The amount of funding available will determine how many individuals will be recruited, the period of the trial and the method of monitoring differences which can be related to their Alzheimer’s disease.

The number of individuals required will to some extent be determined by how they are affected by the mineral water therapy. Large effects could mean statistically significant data from a smaller number of participants.

£500K of funding will support our Alzheimer’s research for three years

Realistically we will require a minimum group size of 50 and the cost of monitoring this number of participants over 24 months will be £500K. This amount of funding will allow us to determine if regular drinking of a silicon-rich mineral water over 2 years influences their cognitive status relative to the accepted ‘normal’ progression of the disease.

Funding in excess of £1M would allow us to complete cognitive studies on a larger number of individuals and extend the current study to include additional treatments

If we can achieve funding above the level of £1M we can look to recruit more individuals into the study, monitor them over a longer period of time and we may also be able to complement cognitive studies with some forms of brain imaging. The latter would be complementary additions and not necessary to test our working hypothesis.  

If we could achieve an exceptional level of funding (significantly above £1M) then we might also look to take advantage of very recent research in my group which has highlighted the importance of sweating and exercise in removing aluminium from the body. Our research suggests that if this mineral water therapy was combined with a specified daily exercise routine then we could expect an even stronger protective effect of the therapy. It would be of interest to create an additional treatment group where daily exercise is added to the mineral water therapy. Exercise has already been shown to be beneficial in individuals with Alzheimer’s disease (Williams PT (2015) Lower risk of Alzheimer’s disease mortality with exercise, statin and fruit intake. Journal of Alzheimer’s Disease 4, 1121-1129.).

We are in the early stages of discussing the specific practical and ethical details of this proposed research trial but a fully informed approval process will be gone through before the trial can commence

Drinking silicon-rich mineral water helps the body to excrete aluminium, raising the possibility of also positively impacting upon Alzheimer’s disease

How can something which sounds so simple be a prospective therapy for Alzheimer’s disease? About 10 years ago we showed that drinking mineral waters which were rich in silicon helped to remove aluminium from the body in the urine. We extended this research to individuals with Alzheimer’s disease and we asked them to drink up to 1.5L of a silicon-rich mineral water each day for 5 days. Over only 5 days we were able to show that silicon-rich mineral waters helped individuals with Alzheimer’s disease to excrete aluminium from their body in their urine8.

We are still looking to understand the mechanism whereby silicon helps to remove aluminium from the body. However, we know that soluble silicon (silicic acid) passes from the gut into the bloodstream and probably forms small complexes called hydroxyaluminosilicates which are then filtered from the blood in the kidney. Silicic acid has no other known chemistry and so can only form complexes with aluminium and is completely safe. Following its movement from the gut into the blood it is then removed from the body via the kidney and urine.

Recently we had the opportunity to test this effect in individuals with Alzheimer’s disease over 12 weeks drinking up to 1L of a silicon-rich mineral water each day. We were able to confirm that silicon-rich mineral waters help to remove aluminium from the body in urine. An additional and perhaps unexpected observation was that during this 12 week period 3 out of 15 individuals with Alzheimer’s disease showed clinically-relevant improvements in their cognitive function during this brief period of time9. This was an exciting result which raised the possibility that the removal of aluminium from the body could impact positively on Alzheimer’s disease.

We now have a mechanism to test the aluminium hypothesis of Alzheimer’s disease

We know that regular drinking of silicon-rich mineral waters over many weeks will slowly and effectively lower the body burden of aluminium. This means that we can take a specific target group of individuals and establish if such a group will benefit from regular consumption of silicon-rich mineral waters. For example, we might ask individuals who have recently received a diagnosis of early stage Alzheimer’s disease to drink 1L of a silicon-rich mineral water every day for 6 or 12 or 18 or 24 months and during this time we will monitor if and how their disease changes. We will be looking for changes in their abilities to perform a range of cognitive tests. These changes in cognitive performance are well established in the ‘normal’ progression of the disease and we will be looking for improvements in these parameters. 

The Working Hypothesis – what we will test in this clinical trial

Our working hypothesis states that if an individual who has recently been diagnosed with early stage Alzheimer’s disease chooses to drink at least 1L of a designated silicon-rich mineral water every day for 24 months that this action will delay the progression of their disease significantly.

We do not know the cause of Alzheimer’s disease

This is in spite of decades of excellent scientific research.

There is no cure for Alzheimer’s disease

Individuals diagnosed as suffering from Alzheimer’s disease have no hope of surviving their disease.

There are no effective treatments for Alzheimer’s disease

None of the 4 drugs which are approved to ‘treat’ Alzheimer’s disease have been proven to be effective in addressing the disease.

Why not aluminium?

Our everyday exposure to aluminium has been linked to Alzheimer’s disease for more than 50 years. The scientific evidence to support a role for aluminium in Alzheimer’s disease is stronger today than at any other time1.

However, there has never been an appropriate clinical trial to unequivocally test a role for aluminium in Alzheimer’s disease.


If you would like to watch Professor Exley talk about this research campaign please click here.

We have all heard about Alzheimer’s disease. We may know someone with the disease. We may have lost a family member to the disease. There are few more terrifying prospects than the diagnosis of this fatal disease. In Europe and the US the prevalence of Alzheimer’s disease is between 3 and 7% of the population, these values rising in females and with age. The direct costs of Alzheimer’s disease can be as high as $30K per person per year (Takizawa et al.,(2015) Journal of Alzheimer’s Disease 43, 1271-1284). Clearly both tax payers and humanity in general will benefit immensely from any positive therapeutic intervention in Alzheimer’s disease.

The subject of aluminium and Alzheimer’s disease remains mired in controversy

If the proposed trial implicates human exposure to aluminium in Alzheimer’s disease then this will represent the most significant advance in the history of the disease. For the first time it will offer everyone the opportunity to protect themselves from Alzheimer’s disease without the need to rely upon expensive medicine and drugs.

This proposed study represents an ideal opportunity for crowdfunding. It is a chance for the people of the world to decide if they want to know if aluminium contributes towards Alzheimer’s disease. It is truly a people’s study and if the people do not think it worthy of support then the enigma of aluminium and Alzheimer’s disease will remain unchallenged.

If like me you do want to know, then like me you will support this proposal.

"I have been researching the toxicity of aluminium for more than 30 years. I am now confident that we are in position to unequivocally test the aluminium hypothesis of Alzheimer’s disease. This confidence comes from research over 30 years describing the unique inorganic biochemistry of aluminium and silicon. I was the first to show that silicon protects against the toxicity of aluminium. I showed that the toxicity of aluminium in fish was completely removed in the presence of silicon. This was my PhD research and it was published in the prestigious journal Nature. Following on from this seminal research we now know that aluminium can be removed from the human body by the simple act of regular drinking of silicon-rich mineral waters.

We now have a method to lower the aluminium content of the body and to measure its impact on disease and specifically in this case Alzheimer’s disease. I am determined that the aluminium hypothesis of Alzheimer’s disease is tested in a clinical trial. We have no conflict of interests in running such a trial. We have nothing to lose financially or otherwise from the outcome or results of this trial. We have only the truth to gain.

I have had the distinct advantage of truly great scientific mentors, such as JD Birchall OBE FRS and RJP Williams FRS, and the privilege of a Royal Society University Research Fellowship. I am grounded in basic science and the scientific method. I do not develop scientific opinions lightly and my opinion on aluminium and Alzheimer’s disease is borne out of the very best research in the field1

I have significant experience in running clinical trials and bringing them to successful conclusions. As Principal or Chief Investigator this includes two previous trials on Alzheimer’s disease, a trial on Parkinson’s disease, one completed trial and one ongoing trial on multiple sclerosis, one completed trial on premature babies and a forthcoming trial on infants as well as numerous trials involving healthy volunteers. Several of these trials (for example, AD, MS, PD and healthy volunteer trials) have involved asking individuals to drink silicon-rich mineral waters. I am currently helping to coordinate a trial in Germany involving individuals receiving immunotherapy and I was recently involved in a clinical trial in France where the body burden of individuals with macrophagic myofasciitis (MMF) was determined. Therefore I am extremely confident that the clinical trial proposed in this appeal will be safe, effective and successful in achieving the stated objectives

If this trial implicates human exposure to aluminium in Alzheimer’s disease then this will represent the most significant advance in the history of the disease. The most significant advance because for the first time it will offer everyone the opportunity to protect themselves from Alzheimer’s disease without the need to rely upon expensive medicine and drugs."

Professor Exley with his research team at the The Birchall Centre

Research into aluminium in The Birchall Centre is internationally renowned and globally respected. We have published more than 150 papers in this field and we are the founders and organisers of the Keele Meetings on Aluminium (1995- 2015).


Rewards are kindly donated by the CMSRI and are therefore in US dollars. Donations in other currencies will be rewarded at the equivalent level 

Gray Matters - $10 

Every bit matters! Thank you for your contribution. Please share our campaign.

Seat at the Table - $25

Thank you for “Thinking” of us! Help us reach our goal and share.

Friend for Life - $50

Abundant appreciation! - Free PDF guide to Aluminum in Everyday products.

Cognitive Collaborator - $100

Our eternal gratitude - Free PDF guide to Aluminum in Everyday products

In Memorium - $250

Remembering those who cannot be forgotten-  Free PDF guide to Aluminum in Everyday products, your loved one recognized in the Keele Aluminum Meeting Program

Sharp as a Tack - $500

Free PDF guide to Aluminum in Everyday products, our abundant thanks. Recognition in the Keele Meeting Program and website.

Generation Sensation - $1,000

Thanks from the heart - 1 DVD of “The Age of Aluminum” featuring Dr. Christopher Exley, Free PDF guide to Aluminum in Everyday products, recognition at the Keele Aluminum meeting and website, our sincere appreciation.

Silver Savior - $2,500

Receive 2 DVD’s of “Age of Aluminum” featuring Dr. Christopher Exley, Free PDF guide to Aluminum in Everyday products, recognition at the Keele Aluminum meeting and website.

Cerebral Celebrity - $5,000  

Receive 3 DVD’s of “The Age of Aluminum” featuring Dr. Christopher Exley, and Free PDF guide to Aluminum in Everyday products, Special recognition at the Keele Aluminum meeting and website, invitation to meet with Dr. Exley.

Beautiful Mind - $10,000 (8 available)

Signed limited edition photograph of your choice and size by  professional photographer Tipper Gore, 3 DVD’s of “The Age of Aluminum” featuring Dr. Christopher Exley and a Free PDF guide to Aluminum in Everyday Products, special recognition at the Keele Aluminum meeting and website, invitation to meet with Dr, Exley.

Thought Leader - $25,000 (8 available ) 

Also receive 5 DVD’s of “The Age of Aluminum” featuring Dr. Christopher Exley, PDF Guide to Aluminum in Everyday products, and a selection of 5 signed published papers on Alzheimer’s disease by Dr. Christopher Exley. Special recognition at the Keele Aluminum meeting and website, Invitation to meet with Dr. Exley.  

Memory Maker $50,000 (4 available)

Donate  $50,000 or more and enjoy a one week stay at a 7 bedroom private luxury villa in the paradise of Jamaica. Sip rum while enjoying the expansive 60-mile panoramic view of the Caribbean and soft breezes. Your generosity will be appreciated and celebrated with gourmet dinners, elegantly served and complimentary champagne. Special recognition will be announced at the Keele Aluminum meeting when the results of the Alzheimer’s study are announced, Certificate artwork honoring your contribution.


More information on the work of Professor Chris Exley at the The Birchall Centre can be found on his lab website:



1. Professor Exley talks more about this campaign and the proposed clinical trial

2. Professor Exley's Inaugural lecture at Keele University

3. Professor Exley discusses aluminium toxity in adjuvants

4. Professor Exley's presentation at  The Vaccine Safety conference in Jamaica, 2011 - The Systemic Toxicity of Aluminium Adjuvants

5. Professor Exley - Human exposure in Aluminium, AutismOne 2015 Conference



1. Exley C (2014) Why industry propaganda and political interference cannot disguise the inevitable role played by human exposure to aluminium in neurodegenerative diseases, including Alzheimer’s disease. Frontiers in Neurology 5:212. doi: 10.3389/fneur.2014.00212.

2. House E, Esiri M, Forster G, Ince PG and Exley C (2012) Aluminium, iron and copper in human brain tissues donated to the medical research council’s cognitive function and ageing study. Metallomics 4, 56-65.

3. Exley C and Vickers T (2014) Elevated brain aluminium and early onset Alzheimer’s disease in an individual occupationally exposed to aluminium: a case report.  Journal of Medical Case Reports 8,41.

4. Exley C & Esiri M (2006) Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. Journal of Neurology Neurosurgery and Psychiatry  77, 877-879.

5. Exley C (2012) Reflections upon and recent insight into the mechanism of formation of hydroxyaluminosilicates and the therapeutic potential of silicic acid. Coordination Chemistry Reviews 256, 82-88.

6. Exley C (2013) Human exposure to aluminium. Environmental Science:Processes and Impacts 15, 1807-1816.

7. Exley C (2009) Darwin, natural selection and the biological essentiality of aluminium and silicon. Trends in Biochemical Sciences 34, 589-593.

8. Exley C, Korchazhkina O, Job D, Strekopytov S, Polwart A & Crome P (2006) Non-invasive therapy to reduce the body burden of aluminium in Alzheimer’s disease. Journal of Alzheimer’s Disease  10, 17-24.

9. Davenward S, Bentham P, Wright J, Crome P, Job, D, Polwart A and Exley C (2013) Silicon-rich mineral water as a non-invasive test of the ‘aluminium hypothesis’ in Alzheimer’s disease. Journal of Alzheimer’s Disease 33, 423-430.


Article PDFs:

Deepika Kassen
Professor Exley gave a short interview on BBC Radio Stoke this morning (15/07/2015) explaining his research. You can listen at: (47min 40sec - 52min 54sec)
15/07/2015 18:32:54
Professor Christopher Exley
Hello and many thanks to all of you who have already donated to this appeal. While your support is highly appreciated inorder for your donation to actually be used to test the link we need you to spread the word about this appeal as widely as possible. Similarly ask others to do the same. I am confident that we can do this together. Best wishes, Chris Exley
16/07/2015 15:58:15
Professor Christopher Exley
Thank you so much to everyone donating to this appeal. It is incredibly hunbling to find out how much individuals care about this and extremely reassuring to know that I am not alone in wanting to see the People's Trial happen. Do use this comments area to ask anything that you want and perhaps to initiate discussion of the appeal and the proposed trial. Do remember that your generous donation will only make a difference if we can reach the funding target so, please do continue to spread the word in every way that you can. My eternal thanks for your support, Chris Exley
24/07/2015 16:04:17
Professor Christopher Exley
Once again, many thanks to everyone making their contribution to this appeal. Over the past 10 years or so I have received many communications from individuals whose health has benefitted from including a silicon-rich mineral water in their daily diet. These anecdotal records have and continue to contribute to my belief that our everyday exposure to aluminium is an increasing factor in chronic human disease. The most recent of these communications came from an individual diagnosed with carpal tunnel syndrome (CTS) in both hands. The aetiology of this disease is unknown but it is linked with diabetes and metabolic syndrome as well as other conditions such as rheumatoid arthritis. The individual was told that the only solution was surgery. Coincidentally this person had heard me on the radio talking about aluminium toxicity and the potential for silicon-rich mineral waters to protect against it. They decided to try this before agreeing to surgery. Within 3 weeks of regular drinking of a silicon-rich mineral water the symptoms of CTS began to disappear and within 12 weeks they had gone completely and have never returned! That was three years ago and the individual contacted me just like week to thank me! Perhaps you have a story that you would like to share with us on this appeal? Best wishes Chris Exley
31/07/2015 09:06:25
J. Michael Burke
Despite Professor Exley’s credentials, he seems a bit naive about clinical research. The description of the proposed clinical trial of the effects of drinking silicon-rich mineral water on early-stage Alzheimer's doesn’t include a control arm or, better yet, two. That is, comparison to a group of similar patients who drink a placebo mineral water and to a group of normals who drink the silicon-containing water. Professor Exley should know enough about research to realize a well-designed RCT is far more valid than a prospective cohort study. His research naivety is also apparent in his discussion of a previous study in which “3 out of 15 individuals with Alzheimer’s disease showed clinically-relevant improvements in their cognitive function during this brief period [12 weeks] of time.” This finding is meaningless given the small number of subjects (15) and the number which purportedly improved. If patients with this disease demonstrate periods of remission then the finding may be due to expected symptomatic remission in some of the subjects, or just regression to the mean. Furthermore, Alzheimer's patients can demonstrate improvement from changes in the environment or in relationships. It is also important to consider that such patients may have other concurrent diseases that can independently contribute to mental impairments, and these other problems may have been improved outside of the study parameters. “The plural of anecdote is not data.”
02/08/2015 19:14:36
Professor Christopher Exley
Thank you J. Michael Burke for your comments. If, as you suggest, you are aware of my 'credentials' then you should also know that I have been involved with many clinical trials and so it is unlikely that I am naïve about clinical research. You, of course, will similarly be aware of the myriad clinical trials on AD that have all failed to show any real efficacy at all. With this in mind I am sure that you will embrace the necessary paradigm shift that is now required in how we take the prevention and treatment of AD forward. We cannot afford another 50 years of failed trials and giving people with AD drugs which benefit only the pharmaceutical industry. People who do know me and my work, such as George Perry at Texas, do not consider either that I am naïve or that the hypothesis in this appeal has no scientific foundation. J Michael Burke can rest assured that when we are in a position to take this trial forward it will be robust and it will provide the information that we all want to know. Namely, how is aluminium involved in AD and how can silicon-rich mineral waters be used as prevention and treatment. Thanks for your comment.
03/08/2015 12:05:35
Professor Christopher Exley
J Michael Burke is correct when he says that the plural of anecdote is not data (is that an old Chinese proverb?). However, I would like to share some additional anecdotal evidence with you about the potential for silicon-rich mineral waters to protect against the toxicity of aluminium. Over the weekend I received an email from someone who had been suffering from ulcerative colitis (UC). They decided to try silicon-rich mineral waters as a possible therapy with the result that their UC has completely gone. Pure coincidence perhaps but interesting anecdotal evidence of something which Louis Pasteur was the first to suggest as a therapy!
03/08/2015 12:15:06
benoit marchal
I really think that it is good to take this initiative and I would love to help (actually my mother is starting to have Alzheimer). Working in the field of clinical trials, I am nevertheless a bit skeptical on the methodology , as Michael, and particularly the absence of placebo control. It is probably not possible (and not ethical) to ask the subjects to not take any medication for AD during this long period. Thus if you notice improvements you will not be able to say if it is coming from the water, the drugs or normal evolution. When it comes to compare to a 'normal’ progression as you suggest, one might still object (true or not) that drug treatments have made progresses since the 'normal' progression has been established. Furthermore, such 'normal' progression is for sure not a well defined value and treatment effect will not be visible in this noise. As you indicated many AD trials failed to demonstrate efficacy and, as most passionate researcher, you believe that your therapy at the difference of all others will show a clear efficacy. Such things are nevertheless very rare and, if successful, a trial usually only show a small efficacy .. and that will be already a big victory. With the wrong methodology you will not detect such small difference and this trial will rather dissuade people to continue in that direction which would be very sad. Placebo control studies are not always possible in alternative medicine, but in this case it seems that it would be feasible: patients following standard treatment would be randomised to receive either a water rich in silicon or another mineral water without silicon. Patients would receive stocks of water in anonymised water bottle. If there is a statistically significant difference between the 2 groups, it will be proven to come from the water then. B. PS: in your scientific background you might want to reference an interesting epidemiological study (which quote you) which prove that people leaving in a region where the water is rich in aluminum have twice more chance to develop AD, while people leaving in a region where the water is rich in silicon had 30% less chance to develop AD ( . The study does not say if providing water rich in silicon could be a treatment (purpose of the study).
29/08/2015 09:12:57
Professor Christopher Exley
I very much appreciate the comment of Benoit Marchal. It will be absolutely essential to get the design of this study specific for purpose so that the results will not be equivocal. For this reason we have not provided a detailed description of the proposed trial in this appeal. We have made it quite clear that the nature of the final trial will be governed primarily by the level of funding available. The trial will only then be submitted for independent peer review and national research ethics approval. The target amount has been calculated based upon a minimum number of participants required to achieve statistical significance between two groups looking only at cognitive function using ADAS-Cog. We will not attempt any study which cannot achieve this and so the study will not go ahead in any form if the target funding is not achieved. Dr Marchal is thanked for highlighting the (French) epidemiological study which, of course, was carried out to test my early research in this field. The concentrations of silicon in the potable waters which proved to be protective against AD were considerably lower than are present in silicon-rich mineral waters and this gives us significant hope that such will be even more effective and especially over 24 months or more. I can only hope that the funding for our proposed study appears from somewhere otherwise we will never know! Thanks again, Chris
31/08/2015 13:39:52
Joel Valento
Dear Professor Exley, I wish the world could see the importance of your research and the see the harmful effects of aluminum on human beings. With so many children being vaccinated with aluminum based adjuvants, the use of aluminum in the food/cosmetic industry, and the thousands of other methods of human exposure to aluminum, most people have no idea of the true harm aluminum causes to neurological systems in human beings. I was vaccinated with Gardasil and lost the ability to walk, talk, concentrate and had auto immune issues directly after vaccination. After doctors failed me and refused to believe it was the vaccine I took matters into my own hands through determined research, and learned from many other peoples suffering in forums. There are many people who were smart enough to realize their child became sick directly after the aluminum filled vaccine, but there are even more that did not put it together. After beginning an aluminum detox using Silicic acid rich water (Fiji) and taking magnesium malate which also aids in aluminum excretion I got my life back. After being a perfectly healthy human being and loosing the ability to walk/talk your life will never be the same, my eyes are open the dangers of aluminum toxicity. I hope the world finds out how important your research is, regardless you have helped me get my life back. If this world has any chance, its because of people like you. Thank you Professor Exley!
07/09/2015 05:33:39
Professor Christopher Exley
Thank you Joel Valento for sharing your experience with everyone. We are very pleased that you were helped by drinking silicon-rich mineral waters. Even if we do not receive the funding required to carry out our clinical trial we hope that many people will include a silicon-rich mineral water in their everyday diet to provide them with protection against the possible toxicity of human exposure to aluminium. Best wishes Chris
09/09/2015 17:00:28
brazier gregory
Hello I'm BRAZIER Gregory agricultural operator in France, but I opted for the financing of projects with the intention of financially support all serious people with projects. So if you need financing and projects, feel free to contact me. Here is my mail:
05/01/2017 19:18:05
Login to post a comment